Fusidic acid

Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update

Retrieved on: 
Wednesday, May 18, 2022
University of Alberta, MBA, CEO, CZO, Company, Infection, Public expenditure, YBG, Administration, Clinical trial, COVID-19, Technology, Research, Mouse, Partnership, McMaster University, Fusidic acid, Methicillin-resistant Staphylococcus aureus, Canada, University, MRSA, Symrise, Polymer, Health Canada, Montreal Heart Institute, Wound healing, GLOBE, Mobile phone, Pharmaceutical industry, Medical device, Online gambling

Our strong financial results this quarter reflect our employees dedication to respond to increased demand in a timely manner.

Key Points: 
  • Our strong financial results this quarter reflect our employees dedication to respond to increased demand in a timely manner.
  • This quarter, we announced a strengthened distribution and supply agreement with long time distributor and partner, Symrise, which will take us throughthe end of 2024.
  • This agreement will provide Ceapro with an additional three years of visibility, stable revenue and cashflows, commented Gilles Gagnon, M.Sc., MBA, President and CEO .
  • Subsequent to quarter, results from development of sodium alginate using PGX Technology were published in the peer review Journal of CO2 Utilization.

Sodium Fusidate Oral: A Bacterial Protein Synthesis Inhibitor by Preventing the Turnover Ofelongation Factor G (EF-G) from the Ribosome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 7, 2021
Health, Pharmaceutical, Chemistry, Protein biosynthesis, Physical sciences, Branches of biology, Diols, Fusidic acid, Desiccants, Protein synthesis inhibitor, EF-G, Sodium, Elongation factor

"SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.

Key Points: 
  • "SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Sodium Fusidate oral, (also known as Fusidic acid, FA or sodium fusidate) acts as a bacterial protein synthesis inhibitor by preventing the turnover ofelongation factor G (EF-G) from the ribosome.
  • What are the other emerging products available and how these are giving competition to SODIUM FUSIDATE ORAL?

Enteris BioPharma to Host Webinar on Strategies for Initiating Phase 1 Clinical Development with Limited API

Retrieved on: 
Tuesday, January 12, 2021
Pharmaceutical industry, Health sciences, Chemistry, Pharmacology, Aminoglycoside antibiotics, Chemical engineering, Tablet, Urinary tract infection, Fusidic acid, Tobramycin, Medication

During the webinar, Mr. Daggs and Mr. Consalvo will discuss their expertise in developing CMC approaches for advancing pharmaceutical companies into Phase 1 clinical development, while managing limited access to active pharmaceutical ingredients, also known as API.

Key Points: 
  • During the webinar, Mr. Daggs and Mr. Consalvo will discuss their expertise in developing CMC approaches for advancing pharmaceutical companies into Phase 1 clinical development, while managing limited access to active pharmaceutical ingredients, also known as API.
  • This webinar, which is the second in a series of virtual events that Enteris is hosting, is designed to share our knowledge and expertise with those who desire novel strategies for initiating clinical programs with limited API quantities."
  • The technologies have been the subject of numerous feasibility studies and active development programs, several of which are in late-stage clinical development.
  • TobrateTM (oral tobramycin tablet) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infection (uUTI).

Recce Pharmaceuticals Announces More Positive Data on RECCE® 327 Against MRSA Superbug in Burn Wound Animal Model

Retrieved on: 
Thursday, April 23, 2020
Infectious diseases, Medical specialties, Medicine, Bacterial diseases, Healthcare-associated infections, Antibiotic-resistant bacteria, Methicillin-resistant Staphylococcus aureus, Pathovars, Staphylococcaceae, Antibiotic, Fusidic acid

The study was conducted by an independent Contract Research Organization to assess the dose-dependency of RECCE 327 and in-vivo antibacterial activity against MRSA in rats with topical burns.

Key Points: 
  • The study was conducted by an independent Contract Research Organization to assess the dose-dependency of RECCE 327 and in-vivo antibacterial activity against MRSA in rats with topical burns.
  • RECCE 327 was effective in reducing bacterial load within a wound and showed enhanced wound contraction in comparison to the best in class - Soframycin.
  • RECCE 327 showed repeated efficacy at different dosing levels on topical skin conditions even at low doses.
  • RECCE 327 continued to show efficacy at different dose levels with significant reduction in bacterial count in the infected wound when compared to the vehicle control (p